The catecholamine dopamine plays a major role in the regulation of cognitive, emotional and behavioral functions, and abnormalities in its regulation have been implicated in a number of psychiatric and neurological disorders. Dopamine acts through D2-like (D2, D3, D4) and D1-like (D1, D5) receptors, which are members of the seven transmembrane segment G protein-coupled receptor (GPCR) superfamily. The long-term goals of this project are: 1) to understand the structural bases of agonist and antagonist binding and specificity in dopamine receptors and related biogenic amine receptors and 2) to determine how agonist binding is transduced into G protein activation. Many drugs used to treat psychiatric disorders, including schizophrenia, attention-deficit hyperactivity disorder (ADHD), and depression, target dopamine receptors, either directly or indirectly. We propose the following specific aims: 1. To determine the functional stoichiometry of the signaling unit of the dopamine D2 receptor (D2R), a representative Family A GPCR. We will determine whether two receptors signal through a single heterotrimeric G protein, the number of agonists required to activate a single signaling unit of D2R, and the role of agonist or antagonist binding to the second protomer in homomeric and heteromeric signaling units. 2. To determine the specificity of D2R heterodimerization in neurons in primary culture and in vivo in Drosophila melanogaster using biochemical, biophysical, and optical methods. 3. To differentiate the role of signaling of D2R homomers and heteromers using a novel resonance energy transfer based-biosensor for G protein activation. To complete our objectives we will combine experimental, structural, and computational approaches to receptor structure and function. In addition to work in heterologous cells, we will use mouse nucleus accumbens medium spiny neurons in primary culture and Drosophila melanogaster as a model system to dissect further the importance of homo- and heteromeric receptor signaling in vivo. Moreover, we will use our newly developed energy transfer based-biosensor to link biophysically the heteromeric receptor complex with G protein activation in real time. 7. PUBLICE

Public Health Relevance

Many drugs used to treat psychiatric disorders, including schizophrenia, attention-deficit hyperactivity disorder (ADHD), and depression, target dopamine receptors, either directly or indirectly. That dopamine receptors may exist and function in homo- and heteromeric complexes with other GPCRs opens new pharmacological possibilities that will be best exploited if based on a clear understanding of the mechanistic basis of this signaling crosstalk.

National Institute of Health (NIH)
National Institute of Mental Health (NIMH)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-MDCN-C (02))
Program Officer
Brady, Linda S
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
New York State Psychiatric Institute
New York
United States
Zip Code
Niswender, Colleen M; Jones, Carrie K; Lin, Xin et al. (2016) Development and Antiparkinsonian Activity of VU0418506, a Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor 4 Homomers without Activity at mGlu2/4 Heteromers. ACS Chem Neurosci 7:1201-11
DeLorenzo, Christine; Gallezot, Jean-Dominique; Gardus, John et al. (2016) In vivo variation in same-day estimates of metabotropic glutamate receptor subtype 5 binding using [11C]ABP688 and [18F]FPEB. J Cereb Blood Flow Metab :
Zou, Mu-Fa; Keck, Thomas M; Kumar, Vivek et al. (2016) Novel Analogues of (R)-5-(Methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one (Sumanirole) Provide Clues to Dopamine D2/D3 Receptor Agonist Selectivity. J Med Chem 59:2973-88
Klein Herenbrink, Carmen; Sykes, David A; Donthamsetti, Prashant et al. (2016) The role of kinetic context in apparent biased agonism at GPCRs. Nat Commun 7:10842
Stolzenberg, Sebastian; Michino, Mayako; LeVine, Michael V et al. (2016) Computational approaches to detect allosteric pathways in transmembrane molecular machines. Biochim Biophys Acta 1858:1652-62
Kruegel, Andrew C; Gassaway, Madalee M; Kapoor, Abhijeet et al. (2016) Synthetic and Receptor Signaling Explorations of the Mitragyna Alkaloids: Mitragynine as an Atypical Molecular Framework for Opioid Receptor Modulators. J Am Chem Soc 138:6754-64
Boateng, Comfort A; Bakare, Oluyomi M; Zhan, Jia et al. (2015) High Affinity Dopamine D3 Receptor (D3R)-Selective Antagonists Attenuate Heroin Self-Administration in Wild-Type but not D3R Knockout Mice. J Med Chem 58:6195-213
Sensoy, Ozge; Weinstein, Harel (2015) A mechanistic role of Helix 8 in GPCRs: Computational modeling of the dopamine D2 receptor interaction with the GIPC1-PDZ-domain. Biochim Biophys Acta 1848:976-83
Frederick, A L; Yano, H; Trifilieff, P et al. (2015) Evidence against dopamine D1/D2 receptor heteromers. Mol Psychiatry 20:1373-85
Donthamsetti, Prashant; Quejada, Jose Rafael; Javitch, Jonathan A et al. (2015) Using Bioluminescence Resonance Energy Transfer (BRET) to Characterize Agonist-Induced Arrestin Recruitment to Modified and Unmodified G Protein-Coupled Receptors. Curr Protoc Pharmacol 70:2.14.1-14

Showing the most recent 10 out of 77 publications